DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Monday reported a loss of $14 million in its third quarter.
The Durham, North Carolina-based company said it had a loss of 7 cents per share.
The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also for a loss of 7 cents per share.
The drugmaker posted revenue of $117.1 million in the period, surpassing Street forecasts. Three analysts surveyed by Zacks expected $114.8 million.
BioCryst expects full-year revenue in the range of $443 million to $448 million.
BioCryst shares have risen 41% since the beginning of the year. The stock has climbed 49% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BCRX at https://www.zacks.com/ap/BCRX
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.